PI3K-Akt-mTOR

PI3K-Akt-mTOR

The PI3K/AKT/mTOR signaling pathway is strongly involved in the fundamental cellular processes of protein synthesis and apoptosis, and disturbed activation of this intracellular pathway has been associated with the development of diseases such as cancer, diabetes mellitus, and autoimmunity. Upon activation of phosphatidylinositol (PI)-3-kinase (PI3K) by extracellular growth factors, phosphorylation of the inner membrane phosphoinositides activates AKT (also known as Protein Kinase B, PKB) and PDPK1 (3-phosphoinositide dependent protein kinase-1). In turn, mTOR (mammalian target of rapamycin) is activated downstream, which plays an important role in cell cycle progression. In many cancer cells, this PI3K/AKT/mTOR pathway is highly active, which can be the result of amplification or mutation of the PI3-kinase gene; amplification or mutation of the Akt gene; or loss of function of PTEN (Phosphatase and tensin homolog). The latter normally regulates the removal of phosphate groups of the PI3K mediated phosphorylated membrane phospholipids, one of the regulating mechanisms to prevent over activations of this pathway.

Read More
sort-descending
  • CHIR98014
    1126
    The price depends on the options chosen on the product page

    From $108.90

  • BX 912
    1130
    The price depends on the options chosen on the product page

    From $88.00

  • Deguelin
    1239
    The price depends on the options chosen on the product page

    From $121.00

  • BEZ 235
    1281
    The price depends on the options chosen on the product page

    From $55.00

  • BAG 956
    1282
    The price depends on the options chosen on the product page

    From $104.50

  • SB 216763
    1303
    The price depends on the options chosen on the product page

    From $93.50

  • PIK 75 hydrochloride
    1334
    The price depends on the options chosen on the product page

    From $77.00

  • PIK 90
    1362
    The price depends on the options chosen on the product page

    From $93.50

  • LY 294002
    1366
    The price depends on the options chosen on the product page

    From $77.00

  • KU-55933
    1367
    The price depends on the options chosen on the product page

    From $121.00

  • GDC 0941 bismesylate
    1377
    The price depends on the options chosen on the product page

    From $88.00

  • PI 103 hydrochloride
    1380
    The price depends on the options chosen on the product page

    From $66.00

  • CHIR99021
    1386
    The price depends on the options chosen on the product page

    From $66.00

  • BX 795
    1390
    The price depends on the options chosen on the product page

    From $66.00

  • Sorafenib tosylate
    1397
    The price depends on the options chosen on the product page

    From $77.00

More About PI3K-Akt-mTOR

The PI3K/AKT/mTOR signaling pathway is strongly involved in the fundamental cellular processes of protein synthesis and apoptosis, and disturbed activation of this intracellular pathway has been associated with the development of diseases such as cancer, diabetes mellitus, and autoimmunity[1]. Upon activation of  phosphatidylinositol (PI)-3-kinase (PI3K) by extracellular growth factors, phosphorylation of the inner membrane phosphoinositides activates AKT (also known as Protein Kinase B, PKB) and PDPK1 (3-phosphoinositide dependent protein kinase-1). In turn, mTOR (mammalian target of rapamycin)  is activated downstream, which plays an important role in cell cycle progression[2]. In many cancer cells, this PI3K/AKT/mTOR pathway is highly active, which can be the result of  amplification or mutation of the PI3-kinase gene; amplification or mutation of the Akt gene; or loss of function of PTEN (Phosphatase and tensin homolog). The latter normally regulates the removal of phosphate groups of the PI3K mediated phosphorylated membrane phospholipids, one of the regulating mechanisms to prevent over activations of this pathway.


[1] PI3K-Akt pathway: its functions and alterations in human cancer. Osaki M, Oshimura M, Ito H. Apoptosis 2004, 9, 667-676.
[2] PI3K/Akt/mTOR pathway as a target for cancer therapy. D. Morgensztern, H.L. McLeod Drugs 2005, 16, 797–803

Loading...